Chairman of the Board, President and Chief Executive Officer, Karuna Therapeutics; Director, Foundation for the National Institutes of Health (FNIH); Former Scientific Director, National Institute of Mental Health (NIMH/NIH)
Dr. Paul is a world-renowned psychiatrist, neuroscientist and drug developer. He is the former president of the Lilly Research Laboratories of Eli Lilly and Company. During his 17 year tenure at Eli Lilly, he held several key leadership positions and in his most recent role, he was responsible for the company’s overall research and development efforts – helping to expand Lilly’s R&D efforts in oncology and biotechnology – resulting in a pipeline of approximately 70 new molecular entities. During Dr. Paul’s time at Lilly, Lilly launched some of the most successful psychiatric drugs of all time including the market-leading antidepressant, Cymbalta, which was developed under Dr. Paul’s direction.
Prior to Lilly, he served as Scientific Director of the National Institute of Mental Health. He has also served as Medical Director in the Commissioned Corps of the United States Public Health Service. Dr. Paul is currently the CEO of Karuna Therapeutics and a Venture Partner at Third Rock Ventures.
Dr. Paul has been the recipient of many awards and honors and has served on numerous committees and advisory boards. He has also authored or co-authored over 500 papers and book chapters, and has recently been appointed to the Science Board of the FDA. He is an elected fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. Dr. Paul is board certified by the American Board of Psychiatry and Neurology.
